Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (TSX: ONC )

1.490 +0.040 (+2.76%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,600
Open 1.460
Bid (Size) 1.450 (118)
Ask (Size) 1.540 (28)
Prev. Close 1.450
Today's Range 1.450 - 1.520
52wk Range 1.200 - 4.490
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
Trial-in-progress abstract highlights new cohort that could expand the company’s pancreatic cancer program Pelareorep’s ability to expand TILs highlights its immunotherapeutic mechanism of action and... 
Via FinancialNewsMedia

Performance

YTD
-15.34%
-15.34%
1 Month
+1.36%
+1.36%
3 Month
+10.37%
+10.37%
6 Month
-32.27%
-32.27%
1 Year
-41.80%
-41.80%

More News

Read More
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
Via FinancialNewsMedia
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Via FinancialNewsMedia
Biotech Innovations Paving the Way in Breast Cancer Fight
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Via FinancialNewsMedia
Exposures Product Safety
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
Via FinancialNewsMedia
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
Via FinancialNewsMedia
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Via Newsfile
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Via FinancialNewsMedia
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
Via FinancialNewsMedia
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire
Cancer Immunotherapy Stocks – Tapping into Immune Systems for Next Generation Treatments
Via FinancialNewsMedia
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
Via Newsfile
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Via FinancialNewsMedia
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
Via FinancialNewsMedia
Pancreatic Cancer Treatments Poised for Major Advances in 2024
Via FinancialNewsMedia
Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
Via FinancialNewsMedia
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
Via FinancialNewsMedia
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
Via FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
From FN Media Group LLC
Via GlobeNewswire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Exposures Death
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.